Fresh Tracks Therapeutics, Inc. Stock

Stocks

28/01/25	Fresh Tracks Therapeutics Announces Special Distribution	CI
16/03/24	Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
21/12/23	Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index	CI
18/12/23	Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from NASDAQ Composite Index	CI
13/11/23	Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
20/09/23	Wall Street Set to Open Wednesday Trading Higher as Investors Await Fed Decision on Interest Rates	MT
20/09/23	US Futures Rise Modestly Pre-Bell as Investors Await Fed Rate Decision	MT
20/09/23	Top Premarket Gainers	MT
20/09/23	Fresh Tracks Therapeutics' Board Approves Liquidation Plan; Shares Rise After Hours	MT
20/09/23	Fresh Tracks Therapeutics, Inc. Announces Chief Executive Officer Changes	CI
20/09/23	Fresh Tracks Therapeutics, Inc. Announces Executive Changes	CI
12/08/23	Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
26/07/23	Fresh Tracks Therapeutics, Inc. Announces Resignation of Robert B. Brown from the Board of Directors, Effective Immediately	CI

14/11/22	Oppenheimer Adjusts Fresh Tracks Therapeutics Price Target to $4 From $9, Maintains Outperform Rating	MT
27/09/22	Oppenheimer Adjusts Price Target on Fresh Tracks Therapeutics to $9 From $1, Maintains Outperform Rating	MT
16/08/22	HC Wainwright Adjusts Brickell Biotech's Price Target to $4.50 From $2, Keeps Buy Rating	MT
13/05/22	Lake Street Downgrades Brickell Biotech to Hold From Buy, Lowers Price Target to $0.25 From $2	MT
13/05/22	Oppenheimer Adjusts Brickell Biotech's Price Target to $1 From $4, Maintains Outperform Rating	MT

26/02/25	Fresh Tracks Therapeutics Announces Dissolution, Initial Cash Distribution and Termination of Trading on the OTC Pink Market	PR
29/01/25	Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution	AQ
28/01/25	/C O R R E C T I O N -- Fresh Tracks Therapeutics, Inc./	PR
06/12/24	Fresh Tracks Therapeutics Announces Hearing Date and Notice of Proposed Consent Judgement Regarding Dissolution of Company	PR
18/06/24	Fresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of Company	AQ

09/03/23	MÄRKTE USA/Uneinheitlich - Zinspfad ungewiss
08/03/23	MÄRKTE USA/Uneinheitlich - Zinssorgen bleiben präsent
08/03/23	MÄRKTE USA/Wall Street mit leichter Erholung
08/03/23	MÄRKTE USA/Wall Street stabilisiert nach Vortagesverlusten
08/03/23	MARKT USA/Wall Street stabilisiert nach Vortagesverlusten

1 day

-0.53%

Manager	Title	Age	Since
Albert Marchio CEO	Chief Executive Officer	74	-
Nancy Seretta CTO	Chief Tech/Sci/R&D Officer	-	01/01/2016
Aaron Fox-Collis DFI	Director of Finance/CFO	-	01/06/2022

Date	Insider	Type	Main position	Quantity	% Market Cap.
07/06/24	Exploration Capital LLC	Buy	Company	405,500	6.7885%
29/05/24	Exploration Capital LLC	Buy	Company	10,434	0.1747%
21/05/24	Exploration Capital LLC	Buy	Company	22,889	0.3832%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FRESH TRACKS THERAPEUTICS, INC.	-0.53%	+2.75%	-	-	5.59M
WUXI APPTEC CO., LTD.	+0.65%	-3.56%	+33.53%	+60.50%	63.48B
ARGENX SE	+1.76%	+1.27%	+11.82%	+82.12%	54.55B
LONZA GROUP AG	-0.94%	+0.99%	+10.45%	+102.18%	53.59B
IQVIA HOLDINGS INC.	+2.17%	+0.45%	+27.39%	+56.85%	44.75B
BEONE MEDICINES AG	+2.42%	-2.90%	+18.44%	+101.10%	41.62B
REVOLUTION MEDICINES, INC.	+0.22%	-4.04%	+220.51%	+916.02%	39.91B
CELLTRION, INC.	+0.64%	-3.85%	+11.71%	+45.57%	32.47B
GENMAB A/S	+29.06%	+47.63%	+107.12%	+94.27%	26.7B
WUXI BIOLOGICS (CAYMAN) INC.	+3.72%	-7.45%	+24.25%	-2.99%	23.36B
Average	+3.92%	-0.42%	+51.69%	+161.74%	42.27B
Weighted average by Cap.	+3.09%	-0.29%	+47.14%	+160.44%